Clinical trial · Observational
Combination Statin, Acetylsalicylic Acid and Dutasteride Use in Prostate Cancer
The Effect of Combination Statin, Acetylsalicylic Acid and Dutasteride Use on Prostate Cancer - a Sub Analysis of the REDUCE Trial
NCT01428869CI-TRIAL-00005473completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess whether there is any interaction between statins, acetylsalicylic acid (ASA) and dutasteride on protection from prostate cancer, the development of high grade prostate cancer, or lower urinary tract symptoms.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (4)
- label
- statin+ASA+dutasteride
- label
- statin+ASA
- label
- dutasteride+statin
- label
- dutasteride+ASA
Primary outcomes (1)
- measure
- Diagnosis of Prostate Cancer
- timeFrame
- 4 years
- description
- The relative risk of prostate cancer development in REDUCE study participants treated with a combination of statins, acetylsalicylic acid and dutasteride.
Secondary outcomes (2)
- measure
- Diagnosis of High Grade Prostate Cancer
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Participants who received dutasteride or placebo and had at least one post-baseline prostate biopsy Exclusion Criteria: * Participants not taking concomitant statins or ASA
References
Publications (0)
Data not yet available
No reference posted for this study.